Rockwell Medical, Inc. (NASDAQ:RMTI) Q1 2022 Earnings Conference Call May 16, 2022 4:15 PM ET

Company Participants

Jason Finkelstein - Investor Relations

Russell Ellison - President and Chief Executive Officer

Russell Skibsted - Executive Vice President, Chief Financial Officer and Chief Business Officer

Marc Hoffman - Chief Medical Officer

Tim Chole - Senior Vice President, Sales and Marketing

Conference Call Participants

Brandon Folkes - Cantor Fitzgerald

Operator

Good afternoon, ladies and gentlemen and welcome to the Rockwell Medical First Quarter 2022 Results Call. [Operator Instructions] As a reminder, this conference call is being recorded. At this time, I would like to introduce Jason Finkelstein, Investor Relations. Please go ahead.

Jason Finkelstein

Good afternoon. This is Jason Finkelstein of Argo Partners, the Investor Relations representative for Rockwell Medical. Joining me from Rockwell Medical on today’s call are Dr. Russell Ellison, President and Chief Executive Officer; and Russell Skibsted, Executive Vice President, Chief Financial Officer and Chief Business Officer. Dr. Marc Hoffman, Chief Medical Officer and Tim Chole, Senior Vice President of Sales and Marketing, will be available for Q&A.

Before we begin, I would like to remind everyone that this conference call and webcast will contain forward-looking statements about the company within the meaning of the federal securities laws, including but not limited to, the types of statements identified as forward-looking in our annual report on Form 10-K and our subsequent periodic reports filed with the SEC, which are all available on our website in the Investor Relations section. These statements are subject to risks and uncertainties that could cause actual results to differ.

Please note that these forward-looking statements reflect our opinions and expectations only as of today. Except as required by law, we specifically disclaim any obligation to update or revise these forward-looking statements in light of new information or future events. Factors that could cause actual results or outcomes to differ materially from those expressed in or implied by such forward-looking statements are discussed in greater detail in our periodic reports filed with the SEC. This conference call could be accessed on Rockwell Medical’s Investor Relations web page. The call is being recorded for audio rebroadcast can also be accessed on the same web page.

At this time, I would like to turn the conference call over to Rockwell Medical’s President and Chief Executive Officer, Dr. Russell Ellison. Russell?

Russell Ellison

Thank you, Jason. Good afternoon and thank you for joining us. Rockwell Medical is a biotech company, but with revenue and that makes us fairly unique. We have a proprietary drug technology called ferric pyrophosphate citrate, or FPC, which is a next-generation therapy for iron deficiency. Iron deficiency is a significant problem in many different patient populations. We believe we have a significant opportunity with FPC in the rapidly growing area of home infusion therapy, where we are confident that there’s a large unmet need for effective iron therapy that FPC can effectively address that unmet need that FPC can be safely administered at the home setting. And based on our prior experience, we can efficiently navigate the clinical and regulatory process.